Loading…
Based on limited metadata with no full letter text available, the FDA issued a warning letter to Superdragon TCM UK Ltd, a company involved with Traditional Chinese Medicine (TCM) products, on August 22, 2019. Without access to the detailed subject line or violation specifics, the precise regulatory concerns cannot be determined from the metadata alone. The warning letter addresses an unspecified product category classified as "Other," indicating the violations likely fell outside standard pharmaceutical or dietary supplement classifications. The issuing office is not identified in the available metadata, limiting clarity on which FDA division oversaw this enforcement action.